Microbioma e doença pulmonar obstrutiva crônica
Palavras-chave:
Doença pulmonar obstrutiva crônica, DPOC, microbiomaResumo
A interação entre o microbioma e o hospedeiro representa a próxima fronteira na Medicina. Evidências crescentes indicam que disbioses do microbioma intestinal e pulmonar, associados a fatores epigenéticos, têm papel na gênese da doença pulmonar obstrutiva crônica (DPOC). De uma maneira integrada e coordenada, o microbioma intestinal e o pulmonar interagem e promovem os mecanismos inflamatórios que resultam nas alterações anatomopatológicas da DPOC. Estudos buscam identificar quais disbioses são responsáveis pelo início dos processos patogênicos. A partir daí, poderão ser desenvolvidos biomarcadores diagnósticos da DPOC capazes de identificar o processo de desenvolvimento da doença antes da sua instalação. Isso permitirá interferir de modo preventivo, evitando disfunções, alterações anatômicas, sofrimento e perda da qualidade de vida nas pessoas sujeitas a desenvolver a DPOC.
Referências
Flandroy L, Poutahidis T, Berg G et cols. The impact of human activities and lifestyles on the interlinked microbiota and health of humans and of ecosystems. Science of the total environment 2018;627:1019-38.
Ursell LK, Metcalf JL, Parfrey LW, Knight R. Defining the human microbiome. Nutr Rev 2012;70(1):S38-S44.
Pflughoeft KJ, Versalovic J. Human microbiome in health and disease. Annu Rev Pathol 2012; 7:99-122.
Albenberg LG & Wu GD. Diet and the intestinal microbiome: associations, functions, and implications for health and disease. Gastroenterology 146, 1564-1572 (2014).
Johnson CL, Versalovic J. The human microbiome and its potential importance to pediatrics. Pediatrics 2012;129(5):950-960.
Modi SR, Collins JJ & Relman DA. Antibiotics and the gut microbiota. J. Clin. Invest 124, 4212-4218 (2014).
Gilbert J, Blaser MJ, Caporaso JG, et cols. Current understanding of the humn microbiome. Nat Med 2018;24(4):392-400.
Cryan JF, Dinan TG, 2012. Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat. Rev. Neurosci. 13, 701-712.
Canfora EE, Jocken JW, Blaak EE, 2015. Short-chain fatty acids in control of body weight and insulin sensitivity. Nat. Rev. Endocrinol. 11, 577-591.
Tan J, McKenzie C, Vuillermin PJ, Goverse G, Vinuesa CG, Mebius RE, et al., 2016. Dietary fiber and bacterial SCFA enhance oral tolerance and protect against food allergy through diverse cellular pathways. Cell Rep. 15, 2809-2824.
Redinbo MR. The microbiota, chemical symbiosis, and human disease. J Mol Biol 2014;426(23):3877-3891.
Goodrich JK et al. Human Genetics Shape the Gut Microbiome. Cell 2014;159, 789-799.
Schirmer M et al. Linking the Human Gut Microbiome to Inflammatory Cytokine Production Capacity. Cell 2016;167, 1897.
Neu, J. The microbiome during pregnancy and early postnatal life. Semin. Fetal Neonatal Med 2016;21:373-379.
Cortese R., Lu L, Yu Y et cols. Epigenome-microbiome crosstalk: apotential newparadigm influencing neonatal susceptibility to disease. Epigenetics 2016;11:205-215.
Paul B, Barnes S, Demark-Wahnefried W et cols. 2015. Influences of diet and the gut microbiome on epigenetic modulation in câncer and other diseases. Clin. Epigenetics 2015;7:112.
de Assis S, Warri A, Cruz MI et cols. High-fat or ethinyloestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring. Nat Commu 2012;3:1053.
Clemente JC, Ursell LK, Parfrey LW et cols. The impact of the gut microbiota on human health: an integrative view. Cell 2012;148: 1258-1270.
Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy. CA Cancer J Clin 2017;67(4):326-344.
Caporaso JG et al. Moving pictures of the human microbiome. Genome Biol 2011;12, R50.
Cho I, Blaser MJ. The human microbiome: at the interface of health and disease. Nat Rev Genet 2012;13(4):260-270.
Dekaboruah E, Suryavanshi MV, Chettri D et col. Human microbiome: an academic update on human body site specific surveillance and its possible role. Archieves of Microbiology 2020;202:2147-67.
Bernet MF, Brassart D, Neeser JR, Servin AL (1994). Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 1994;35(4):483-489.
Lievin V, Peiffer I, Hudault S et cols. Bifidobacterium strains from resident infant human gastrointestinal microflora exert antimicrobial activity. Gut 2000;47(5):646-652.
Arianna K, DeGruttola BS, Daren L et cols. Current understanding of dysbiosis in disease in human and animal models. Inflamm Bowel Dis 2016;22(5):1137-1150.
P. Gerard. Gut microbiota and obesity. Cellular and Molecular Life Sciences 2016;73(1):147-162.
Kim S, Covington A, Pamer EG. The intestinal microbiota: antibiotics, colonization resistance, and enteric pathogens. Immunological Reviews 2017;279(1):90-105.
Belizário JE, Napolitano M. Human microbiomes and their roles in dysbiosis, common diseases, and novel therapeutic approaches. Front Microbiol 2015; 6:1050.
Dickson RP, J. Erb-Downward R, Martinez FJ et col. The microbiome and the respiratory tract. Annual Review of Physiology 2016;78(1):481-504.
Wilson M. Microbial Inhabitants of Humans. Chapter 4: The respiratory system and its indigenous microbiota. Cambridge Univ Press, Cambridge, 2005; pp 128-178.
Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol 2017;15(5):259-270.
Gao Z, Kang Y, Yu J, Ren L. Human pharyngeal microbiome may play a protective role in respiratory tract infections. Genom Proteom Bioinf 2014;12(3):144-150.
Biesbroek G, Tsivtsivadze E, Sanders EA, Montijn R, Veenhoven RH, Keijser BJ, Bogaert D. Early respiratory microbiota composition determines bacterial succession patterns and respiratory health in children. Am J Respir Crit Care Med 2014;190(11):1283-1292.
Kelly BJ, Imai I, Bittinger K, Laughlin A, Fuchs BD, Bushman FD, Collman RG. Composition and dynamics of the respiratory tract microbiome in intubated patients. Microbiome 2016; 4(1):7.
Dickson RP, Erb-Downward JR, Martinez FJ, Huffnagle GB. The microbiome and the respiratory tract. Annu Rev Physiol 2016; 78:481-504.
Global Initiative for Chronic Obstructive Lung Disease – GOLD. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease. Gold Report 2021.
Halpin DMG, Celli BR, Criner GI et cols. The GOLD Summit on chronic obstructive pulmonar disease in low- and Middle-income countries. Int J Tuberc Lung Dis 2019;23(11):1131-41.
Mathes CD, Loncar D. Projections of global mortality and burden of desease from 2002 to 2030. PLoS Med 2006;3(11):e442.
Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022;10(5):497-511.
Wood AM, Stockley RA. The genetics of chronic obstructive pulmonar disease. Respir Res 2006 ;7(1):130.
Celli BR, MacNee W, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23(6):932-46.
ATS: Chronic bronchitis, asthma and pulmonary emphysema: a statement by the committee on diagnostic standards for non-tuberculous respiratory diseases. Am Rev Resp Dis 1962, 85:762-768.
Snider GL, Kleineman J, Thurlbeck WM, Bengali ZK: The definition of emphysema: a report of the National Heart, Lung and Blood Institute, Division of Lung Diseases Workshop. Am Rev Resp Dis 1985, 132:182-185.
Agusti AG. Systemic effects of chronic obstructive pulmonar disease. Proc Am Thorac Soc 2005, 2(4):367-70; discussion 371-2.
Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol 2015;31(1):69-75.
Samuelson DR, Welsh DA, Shellito JE. Regulation of lung immunity and host defense by the intestinal microbiota. Frontiers in Microbiology 2015;6:1085.
Li J, Jia H, Cai X et cols. MetaHIT Consortium. An integrated catalog of reference genes in the human gut microbiome. Nat Bio Technol 2014;32:834-841.
Chunxi L, Haiyue L,Yanxia L et cols. The Gut Microbiota and Respiratory Diseases: New Evidence. J Immunol Res 2020;2020:2340670.
Mammen MJ, Sethi S. COPD and the microbiome. Respirology 2016;21:590-9.
Erb-Downward JR, Thompson DL, Han MK, et al. Analysis of the lung microbiome in the ‘healthy’ smoker and in COPD. PLoS ONE 2011; 6: e16384.
Sze MA, Dimitriu PA, Hayashi S et cols. The lung tissue microbiome in chronic obstructive pulmonar disease. J Clin Microbiol 2012;50:3562-8.
Grunig G, Baghdassarian A, Park S-H et cols. Challenges and current efforts in the development of biomarker for chronic inflammatory and remodeling conditions of the lungs. Biomarker Insights 2015;10(S4):59-72.
Sin DD, Miller BE, Duvoix A, et al. ECLIPSE Investigators. Serum PARC/ CCL-18 concentrations and health outcomes in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011;183(9):1187-92.
Agustí A, Edwards LD, Rennard SI, et al. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One. 2012;7(5):e37483.
Yamamoto M, Tochino Y, Chibana K, Trudeau JB, Holguin F, Wenzel SE. Nitric oxide and related enzymes in asthma: relation to severity, enzyme function and inflammation. Clin Exp Allergy. 2012;42(5):760-8.
Kanazawa H, Yoshikawa J. Elevated oxidative stress and reciprocal reduction of vascular endothelial growth factor levels with severity of COPD. Chest. 2005;128(5):3191-7.
Vogelmeier CF, Román-Rodríguez M, Singh D et cols. Goals of COPD treatment: Focus on symptoms and exacerbations. Respir Med 2020;166:105938.
Celli BR, Singh D, Vogelmeier C et col. New Perspectives on Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2022;17:2127-2136.
Bhatt SP, Blauer-Peterson C, Buysman EK et cols. Trends and Characteristics of Global Initiative for Chronic Obstructive Lung Disease Guidelines-Discordant Prescribing of Triple Therapy Among Patients with COPD. Chronic Obstr Pulm Dis 2022;9(2):135-153.
Miravitlles M, Auladell-Rispau A, Monteagudo M, et cols. Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD. Eur Respir Ver 2021;30(160):210075.
Yagi K, Huffnagle GB, Lukacs NW et col. The lung microbiome during health and disese. Int J Mol Sci 2021;22:10872.
